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In recent years the greatest progress in our understanding of pneumoconioses, other than those
produced by asbestos, silica, and coal, has been in the arena of metal-induced parenchymal lung
disorders. Inhalation of metal dusts and fumes can induce a wide range of lung pathology, including
airways disorders, cancer, and parenchymal diseases. The emphasis of this update is on
parenchymal diseases caused by metal inhalation, including granulomatous disease, giant cell
interstitial pneumonitis, chemical pneumonitis, and interstitial fibrosis, among others. The clinical
characteristics, epidemiology, and pathogenesis of disorders arising from exposure to aluminum,
beryllium, cadmium, cobalt, copper, iron, mercury, and nickel are presented in detail. Metal fume
fever, an inhalation fever syndrome attributed to exposure to a number of metals, is also discussed.
Advances in our knowledge of antigen-specific immunologic reactions in the lung are particularly
evident in disorders secondary to beryllium and nickel exposure, where immunologic mechanisms
have been well characterized. For example, current evidence suggests that beryllium acts as an
antigen, or hapten, and is presented by antigen-presenting cells to CD4+ T cells, which possess
specific surface antigen receptors. Other metals such as cadmium and mercury induce nonspecific
damage, probably by initiating production of reactive oxygen species. Additionally, genetic
susceptibility markers associated with increased risk have been identified in some metal-related
diseases such as chronic beryllium disease and hard metal disease. Future research needs include
development of biologic markers of metal-induced immunologic disease, detailed characterization of
human exposure, examination of gene alleles that might confer risk, and association of exposure
data with that of genetic susceptibility. Key words: aluminum, beryllium, cadmium, cobalt, copper,
hard metal disease, iron, mercury, metal fume fever, nickel, pneumoconiosis. - Environ Health
Perspect 108(suppl 4):685-696 (2000).
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The term pneumoconiosis, first introduced in
the 19th century, refers to diseases and patho-
logic consequences from inhalation ofparticu-
late dusts. In recent years the greatest progress
in our understanding of pneumoconioses,
other than those produced by asbestos, silica,
and coal, has been in the arena of metal-
induced parenchymal lung disorders. As pre-
sented in Table 1, various metal dusts and
fumes can induce awide range oflung pathol-
ogy, including not only parenchymal diseases
but airways disorders and cancer as well. In
this update we emphasize the parenchymal
diseases caused by metal inhalation, including
granulomatous disease, giant cell interstitial
pneumonitis, chemical pneumonitis, and
interstitial fibrosis, among others. Although a
number ofmetals, in addition to those dis-
cussed in this chapter, are associated with vari-
ous forms oflung injury, we have focused this
discussion on those forwhich there has been a
significant increase in ourknowledge in recent
years. The sections below are organized by
metal type, and in some cases we emphasize
new developments in clinical understanding,
epidemiology, or basic pathogenesis, depend-
ing upon where the most progress has been
made. Most ofthe disorders arise from occu-
pational exposures; however, some may occur
secondary to environmental exposures such as
mercury-induced chemical pneumonitis. A
more detailed discussion ofall ofthe metals
associated with lung disorders was presented
in a previous publication (1). A major theme
that emerges in reviewing recent develop-
ments in metal-related lung toxicity is the
extent to which various metals are capable of
inducing both antigen-specific immunologic
reactions in the lung and nonspecific "innate"
immune system responses characterized by
inflammation frequently triggered by oxidant
injury. With the recognition ofthese immune
and inflammatory effects comes a growing
awareness ofthe potential hazards to the lung
at lowlevels ofexposure. There is also increas-
ing research being conducted on the interac-
tion between metal exposure and the human
genome. In the cases ofberyllium and cobalt,
for example, there is emerging recognition of
the specific genetic risk factors associated with
susceptibility to exposures that promote
metal-induced parenchymal disease.
Aluminum
Aluminum is the most abundant metal found
in the earth's crust. Aluminum ore (bauxite)
is mined in open pits, resulting in potential
exposure to silica and aluminum silicates. The
bauxite ore is washed, ground, and dissolved
in a hot caustic solution, resulting in alumina
(A1203) precipitate. The alumina is converted
to aluminum by an electrothermal process in
a reduction cell (carbon-lined steel container).
A number ofthese cells or pots are arranged
in lines in a potroom. Carbon monoxide,
carbon dioxide, polynuclear aromatic hydro-
carbons, aluminum fluoride, and particulates
are released in this process.
A number ofpulmonary effects have been
attributed to aluminum exposure. Potroom
asthma has been recognized since the 1930s
(2-5), with estimates ofprevalence from 0 to
39% ofpotroom workers (3-5). Other disor-
ders include chronic bronchitis, pulmonary
fibrosis, granulomatous lung disease, acute
tracheobronchitis, pneumonitis, and pul-
monary edema (6). The respiratory effects
depend to some extent on the form ofalu-
minum or stage in processing in which expo-
sure occurs. In this section we review the
parenchymal disorders associated with the
production and manufacturing ofaluminum
and aluminum products.
Parenchymal disease was first described in
aluminum refineries by Shaver and Riddell in
the 1940s (7,8). They found X-raychanges in
10% offurnaceworkers exposed to aluminum
abrasives. The workers were exposed to dense
fumes containing alumina and silica when the
tops of the pots were opened. The workers
were dyspneic and producedwhite frothyspu-
tum. ChestXrays showed evidence offibrosis,
blebs, and bullae. At autopsy, lung ash con-
tained 21-31% silicaand 26-40% alumina.
More recently, Saia et al. (9) observed
chest X-ray changes consistent with pneumo-
coniosis in 30% of potroom workers com-
pared to 15% in controls. Long-term workers
were more likely to have evidence ofpneumo-
coniosis. In anArkansas bauxite refinery, chest
X-ray irregular opacities were observed in 4%
of nonsmokers and 12% of smokers (10).
Kilburn andWarshaw reported irregularopac-
ities in 20.7% of670 aluminum workers in
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Table 1. Histopathology of metal-induced disease.
Agent Characteristic histopathology
Aluminum Interstitial fibrosis
Beryllium Sarcoidlike granulomas; diffuse interstitial fibrosis
Cadmium Acute pneumonitis; interstitial fibrosis; emphysema
Cobalt Giantcell interstitial pneumonia; desquamative
interstitial pneumonitis; fibrosis
Copper Foreign bodygranulomas; fibrosis
Iron Dust macule; peribronchiolar collections ofdust
with dust-laden macrophages
Mercury Tracheobronchitis; bronchiolitis; pneumonitis;
pulmonary edema; desquamative interstitial
pneumonitis(late)
Nickel Asthma; epithelial dysplasia; chemical pneumonitis
Alabama. The pattern was characterized by
evenly distributed fine opacities extending
from apex to base, including retrosternal and
retrocardiac areas on lateral chestXray(11).
Parenchymal disease has also been reported
from exposure to refined aluminum powder.
Stamped aluminum powder is used in the man-
ufacture ofpyrotechnics and aluminum dyes.
Reports ofsevere fibrosis ofthe lungs due to
exposure have been primarily from European
sources (12-15), and a dose-response relation-
ship has been suggested. Cases in North
America have been infrequently reported (16).
In 1996 Sjogren et al. (17) reviewed five cases
ofaluminosis diagnosed in the late 1940s by
miliary or linear chest radiograph abnormali-
ties and attributed to occupational exposure
to stamped aluminum powder. The two
cases who survived had no respiratory symp-
toms, and their vital lung capacities had not
deterioratedduringtheinterveningyears.
Interestingly, DeVuyst et al. (18) reported
a case of sarcoidlike granulomatosis in a
chemist who worked with aluminum pow-
ders. A recent case oflung granulomatosis
attributed to occupational exposure to beryl-
lium and aluminum has also been reported in
adental laboratory technician (19).
Occupational exposure to aluminumwhile
grinding, polishing, andwelding also has been
associated with parenchymal lung disease.
There have been limited reports ofpulmonary
effects from grinding and polishing ofalu-
minum. A case ofalveolar proteinosis (20)
and a case offibrosis (21) have been reported.
In a cross-sectional study, aluminum oxide
dust was associated with abnormal chest
Xrays in 9 of1,000 workers producingA1203
abrasives. Three workers had lung biopsies
that showed interstitial fibrosis with honey-
combing (13). Aluminum-containing welding
fumes have been credited as the causative
agent in case reports ofpulmonary fibrosis
686
Beryllium
Otherreported histopathology
Sarcoidlike granulomas;
alveolarproteinosis
Tracheitis; bronchitis;
acutepneumonitis
Sarcoidlike granulomas
Fibrosis
Proteinuria; acute tubular
necrosis; neurotoxicity
Nasal septal perforation;
chronic rhinitis; hyper-
plastic sinusitis; anosmia
(22), interstitial pneumonia (.
pulmonary granulomas (24), bu
sectional study of 64 aluminum
workers, albeit limited by small sai
failed to show evidence ofpulmona
(25). Thin-section computed tor
findings in aluminum polishers am
were reported recently by Akira (.
characterized three forms: predo
reticular fibrosis, predominantl)
fibrosis, and upper lobe fibrosis. Th
in reticular fibrosis are similar tc
usual interstitial pneumonia. TI
nodular fibrosis may have ill
centrilobular nodules diffusely di
through both lungs. In two cases, u
fibrosis was seen and mayhave been
ahistoryoftuberculosis.
The pathogenesis ofaluminur
parenchymal disorders is unclear. A
fibers persisted in the respiratory trac
than 4 years in workers with occi
exposure (27). The dinical significai
findingis undear. In animal studies,,
oxideisconsiderednonfibrogenic, sin
tion ofaluminum oxide results in oi
transient inflammatory response (2E
in contrast to known fibrogenic agen
silica, that produce a persistent and F
inflammatoryresponsein thesamem
In rats, intratracheal instillation offive
used for primary aluminum prn
showednofibrogenicpotential (29).
In summary occupational e:
during the production and refinir
minum have been associated with
coniosis, fibrosis, and granulomat
disease. The prevalence ofdisease iI
workers is not well characterized bt
low compared to beryllium c
(described in the next section). Th
nisms responsible for aluminum
parenchymal disease remain poorlyd
References (7,15,20) Some ofthe most interesting progress in the
(13,18,21) study of metal-induced parenchymal lung
disease has occurred regarding beryllium, par- (194,195) ticularly chronic beryllium disease (CBD).
The past decade has seen advances in our
(812) understanding ofthe epidemiology ofCBD a
(82,85) revolution in the methods ofdisease detection
in the workplace and in the use ofnew diag-
(117,118) nostic tools based on immunology, and
(196) improvement in our understanding of the
immune basis and immunogenetics ofthis
(1,142) disease. Recently, progress has also been made
in refining our understanding of the
exposure-response relationship for CBD. In
(174) this next section we will emphasize the devel-
opments made in the relationship between
genetics and exposure response.
Beryllium is the fourth lightest element.
It has low density, a high melting point, and
23), and high tensile strength, which has led to its
t a cross- incorporation into many high-technology
l-exposed applications. Exposures occur in the extrac-
mple size, tion ofthe mineral from its ores and in the
.ry fibrosis processing ofberyllium into metal alloys,
nography ceramic products, and metal salts. The sec-
d smelters ondary machining and processing ofberyl-
26), who lium alloys and ceramic products in
minantly industries (e.g., electronics, aerospace,
f nodular machining, and nuclear weapons manu-
e findings facture) has resulted in an ongoing epidemic
those of ofCBD. This disease is a granulomatous dis-
lose with order that affects principally the lungs, lym-
I-defined phatics, and skin. Although we have known
istributed about CBD for more than 50 years [since its
pper lobe description by Hardy and Tabershaw (30)],
related to the disease continues to occur. The reduction
ofberyllium levels in the workplace has led
m-related to a reduction in the incidence of acute
luminum pneumonitis from beryllium. However,
t for more CBD is an ongoing problem in industry,
upational affecting between 2 and 6% of workers.
nce ofthis Attack rates as high as 16% have been associ-
aluminum ated with some tasks/job titles in industry.
Lce instilla- Although the exact number of beryllium-
nly a mild exposed workers is hard to determine, esti-
9). This is mated numbers ofworkers exposed range as
its, such as high as 800,000 in the United States alone.
)rogressive Individuals who are exposed to beryllium
odel (28). fall into three major categories: a) those who
caluminas show no evidence ofan immune response to
oduction beryllium and no chronic beryllium disease;
b) those who are sensitized to beryllium, as
xposures measured bythe blood beryllium lymphocyte
ig ofalu- proliferation test (BeLPT) or other measure
pneumo- ofspecific immune response to beryllium,
tous lung but who do not yet have any evidence of
n exposed CBD; and c) those who show evidence of
it appears sensitization and CBD-a granulomatous or
exposure mononuclear cell infiltration ofthe lung and
e mecha- beryllium-specific immune response in
-induced blood, lung, or skin by the BeLPT or skin
lefined. patch test (31).
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The evidence to date suggests that beryl-
lium acts as an antigen, or hapten, and is
presented by antigen-presenting cells in the
context ofa major histocompatibility complex
(MHC) class II molecule to CD4+ T cells,
which possess T-cell antigen receptors on their
surface capable of recognizing the antigen
moiety. Recent studies show that in CBD
there is preferential use ofparticular T-cell
receptor subfamilies in the lungs compared to
the blood (32), and that these T cells are
beryllium-specific clones. A striking degree of
oligoclonality has been observed in our
patients with CBD, with approximately one-
third ofthe patients showing preferential use
ofT cells expressing the variable region ofthe
beta subunit ofthe T-cell receptor (V,B3) in
the lung. Bysequencing the complementarity-
determining regions (CDR) ofthese patients'
VP and matching Vapartners, Fontenot et al.
(32) have shown that there are trueberyllium-
reactive T-cell clones in the lungs and that
these clones persist over time. These data sug-
gest that CBD is the consequence ofan anti-
gen-recognition event. As the antigen persists,
so does the specific clonal selection in the pul-
monary compartment. The absence ofV,33
clones in the remainder ofpatients suggests
that other subsets ofT-cell clones participate
in antigen recognition aswell.
There is longstanding evidence that these
T cells recognize the beryllium antigen moi-
ety in the context ofClass II MHC molecule
presentation. In a study by Saltini and col-
leagues (33), beryllium-specific lymphocyte
proliferation was blocked by the use ofanti-
bodies against human leukocyte antigen
(HLA-D). The study by Saltini et al. led to
examination ofthe genetic risk factors associ-
ated with the human HLA. Richeldi and col-
leagues have subsequently shown that CBD
patients, compared to beryllium-exposed
nondiseased controls, bear a genetic suscepti-
bility marker, HLA-DP,B1 Glu69, in which
there is allelic substitution ofa glutamate in
position 69 on the HLA-DP P1 encoding
allele (34). This study by Richeldi et al. was
the first to document a gene association in
CBD, and suggested that there may be a
potentially important antigen-binding site
involved in antigen presentation (34,35). The
Glu69 substitution has been found in
85-95% of CBD patients, compared to
30-45% ofcontrols in subsequent studies.
Most such studies have been performed using
a case-control methodology. One study has
looked at this gene marker in a population-
based context, as discussed below. The aggre-
gate data suggest that more than one HLA
marker-and possibly more than one antigen
presentation site-may be involved in beryl-
liumantigen recognition.
Understanding the genetics ofCBD tells
only part ofthe story. No one develops CBD
unless they have been exposed to beryllium.
Ironically, at this pointwehave abetter under-
standing ofthe nature ofthe immune response
and the genetics ofberyllium disease than we
have ofthe nature ofthe beryllium exposure
that leads to thedisease. Itwould be important
to have a better understanding ofexposure for
several reasons. First, since the downsizing of
nuclear weapons production worldwide, there
is a surplus ofberyllium that formerly went
into nuclear weapon production and which is
now finding its way into a wider variety of
industries, including automotive, computers,
electronics, aerospace, and high-tech preci-
sion-machined products. Thus, an increasing
number ofpeople worldwide have potential
exposure to beryllium in the form ofdust or
fume, as beryllium finds its way into more
and more products being manufactured. The
disease occurs, on average, in 2-6% of
exposed individuals. However, in some indus-
trial settings the attack rates are as high as
17% (36-38). The epidemiologic data to date
show that the 2-pg/m3 8-hr time-weighted
average Occupational Safety and Health
Administration (OSHA) standard is not suffi-
ciently protective against CBD (31). Second,
although some individuals such as security
guards, secretaries, andother front officework-
ers develop disease after seemingly trivial levels
of exposure, there is also evidence for an
exposure-response and a dose-response rela-
tionship for the development ofthis disease.
For example, machinists in the beryllium
industryhavehigherexposuresanddevelop dis-
ease at rates ranging from 4 to 11%. In astudy
conducted at oneberyllium ceramics company,
Kreiss et al. (38) observed that there was an
excess rate ofdisease among machinists in the
plant and that these machinists had, on aver-
age, higher daily exposures to beryllium than
other workers. Interestingly, nearly all air-sam-
pling measurements were found to be below
the current OSHA standard for exposure (38).
Thus, an exposure-response relationship can
be found even among those exposed to low
levels ofberyllium. In a follow-up study,
Richeldi et al. (39) tested for the presence of
the Glu69 genetic marker in this same work
force. In that population-based study, presence
ofthe Glu69 marker conferred approximately
a 10-fold risk ofberyllium disease. Exposure,
as measured by machining history, conferred
an approximately 8-fold risk ofberyllium dis-
ease. These two significant risk factors con-
tributedindependently to theoverall risk (39).
In an effort to better understand the role
of exposure in this disease process, several
research groups are nowexamining the nature
of beryllium particles and the relation of
exposure characteristics plus genetics to dis-
ease risk. One such study in a beryllium pre-
cision machine shop observed that when
beryllium is machined, whether bydeburring,
grinding, lapping, lathing, milling, or other
processes, and whether machined dry or with
metalworking fluids, the size distribution of
the beryllium particulate aerosol is bimodal.
Approximately one-quarter to one-third of
the beryllium is liberated as large particles
(> 10 pm in median aerodynamic diameter).
The remainder is liberated into the air as res-
pirable-size partides, with a strong predomi-
nance (30-50% by mass) of particles
< 0.6pm aerodynamic diameter. Thus, beryl-
lium machining operations produce a dis-
persed particulate that is highly respirable and
that can deposit in the deepest portions ofthe
lung at the alveolar level. Furthermore, as a
consequence ofmachining, a submicron-size
(< 0.6 pm) particulate cloud ofberyllium dis-
perses throughout the entire work site (40).
This may explain why disease occurs in front
office workers as well as among those more
directly involved in beryllium production.
GeneticsofInflammaonandFlbrosis
Based on our current understanding ofCBD
and ofberyllium itself, it has become increas-
ingly apparent that beryllium acts in two
major ways: a) it acts antigenically (probably
in the form ofa beryllium-hapten complex),
and b) beryllium itselfhas adjuvant proper-
ties, in part because ofits ability to induce the
production oftumor necrosis factor (TNF)-a
and other proinflammatory molecules in
inflammatory macrophages (41-43). Thus, it
is important to consider not only those
genetic factors that may favor beryllium's
recognition as an antigen (i.e., sensitization),
but those other factors that may predispose to
the progression from beryllium sensitization
to chronic and end-stage inflammation and
fibrosis. Given that CBD often has a relent-
less progressive course, recent research has
begun to focus on identifying those factors
that can help prognosticate and detect those
patients athighest riskofprogressive disease.
When one examines the noncaseating
granuloma in CBD or in sarcoidosis, or other
histologically related granulomatous disor-
ders, it is common to observe a surrounding
cuff of dense collagen interspersed with
numerous mast cells and fibroblasts (44).
Thus, it may be important to consider the
ways in which individuals vary in their
expression ofa profibrotic clinical phenotype
and relate this to genetic and exposure risk
factors. Toward this goal, Richeldi et al. (34)
searched for TNF-a polymorphisms in the
same case-control study in which they looked
for the Glu69 marker. They found no associ-
ation between TNFB*1 allele polymorphisms
and this disease. Recently, Maier et al. (45)
examined the role ofangiotensin converting
enzyme (ACE) polymorphisms in CBD in a
case-control study comparing cases ofberyl-
lium disease to two control groups-those
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who were beryllium exposed and non-
diseased, and those who were not beryllium
exposed. ACE, which converts angiotensin-I
to angiotensin-IT in the lung, has been impli-
cated in the immune response in granuloma-
tous diseases and may be important in
regulating the fibrotic response. CBD
patients with the ACE genotype DD had
higherACE levels, tended to become diseased
at an earlier age, and had fewer total years of
beryllium exposure. Furthermore, the DD
cases tended to have a lower peak blood and
bronchoalveolar lavage (BAL) BeLPT stimu-
lation index (45). These data suggest the pos-
sibility that the ACE genotype may confer
riskofdisease severity and earlier onset.
Future research on the relationship
between genetics and CBD progression will
need to focus on other immunoregulatory
genes involved in granuloma formation and
the antigenic response. Specifically, Tinkle
and colleagues (41) have observed that beryl-
lium induces BAL cells to produce large
amounts of y-interferon, interleukin (IL)-2
but not IL-4 in CBD. In addition, these cells
produce large amounts ofTNF-a and IL-6
(42,46). Thus, the emerging portrait is that
of a T-helper 1 (Thl) cytokine milieu in
CBD. As we learn more about the genetic
polymorphisms that regulate these cytokines,
it will become possible to better understand
the genetic regulation ofthe proinflammatory
factors that promote metal-induced Thl-type
granuloma formation and maintenance.
Cadmium
Exposure to cadmium occurs in production of
nickel cadmium batteries, electroplating, man-
ufacture ofpigments, and manufacture ofcad-
mium alloys. Smokers have cadmium
exposure, since every cigarette contains
approximately 2 pg cadmium. Cadmium has
a low boiling point and high vapor pressure.
Consequently, cadmium fumes may be gener-
ated in toxic concentrations from cadmium
welding and soldering, and in the production
ofcadmium alloys. Acute inhalation ofsuffi-
cient exposure can cause both a chemical
pneumonitis and pulmonary edema from the
toxic effect to the alveolar epithelium and
endothelium (1). Within 24 hr ofexposure,
workers develop shortness ofbreath, fever,
and fatigue, which can progress to pulmonary
edema and death (47,48). Symptoms are sim-
ilar to metal fume fever and may be associated
with impairment in pulmonary function and
leukocytosis (49). Survivors may develop
interstitial fibrosis and emphysema (47).
Chronic exposure to cadmium dusts and
fumes has been suspected as a cause of
emphysema, obstructive lung disease, pul-
monary fibrosis, and lung cancer. Early
studies, however, did not account for the
effect of smoking. In 1983, an increased
mortality from bronchitis, compared to
expected, was reported in 434 cadmium
workers (50). A later study in the same
cohort confirmed this finding (51). Davison
et al. (52) studied pulmonary function and
chest radiographs in 101 workers in a copper
cadmium alloyproduction plant. In compari-
son to nonexposed workers, cadmium work-
ers showed evidence of emphysema,
including airflow limitation, hyperinflated
lungs, and a reduction in diffusing capacity.
A study in 347 copper cadmium alloy work-
ers showed an increased risk of mortality
from chronic nonmalignant diseases of the
respiratorysystem (53).
The mechanism of cadmium-induced
pulmonary damage is an area under current
investigation. Animal experiments have
shown that inhalation ofcadmium chloride
results in emphysema and fibrosis (54-56).
In hamsters, air-space enlargement and pul-
monary fibrosis were not associated with
reductions in collagen or elastin (55). This
finding led Snider et al. (55) to conclude that
air-space enlargement was due to overdisten-
tion ofless abnormal air spaces by fibrotic
and atelectatic areas. In vitro, cadmium
induces oxidative cellular damage, including
lipid peroxidation and production ofreactive
oxygen species in human fetal lung fibroblasts
(57), and release of oxidant radicals from
guinea pig alveolar macrophages (AMs) (58).
Alveolar epithelial type 2 cells develop resis-
tance to oxidant-induced cytotoxicity after
repeated exposure to cadmium aerosols (59).
This resistance was also shown in human
lung fibroblasts and correlated with increased
production ofmetallothionein, a scavenger of
reactive oxygen species (60). Recently,
Chambers et al. have shown that cadmium
salts inhibit fibroblast procollagen production
(61) and proteoglycan synthesis (62) in vitro.
The authors suggest that inhibition ofpro-
duction ofconnective tissue proteins, essen-
tial for repair following injury, may
contribute to cadmium-induced emphysema.
In summary, acute exposure to cadmium
fumes can result in a severe chemical pneu-
monitis. Epidemiologic studies suggest
chronic exposures are also associated with
adverse pulmonary effects such as emphysema
and pulmonary fibrosis. Similar to cobalt
exposure described below, oxidant-induced
cytotoxicity may be the event initiating
pulmonarydamagefrom cadmium inhalation.
Cobalt and Hard Metal Disease
Hard metal is a metal matrix that consists
predominantly ofcobalt metal and tungsten
carbide partides. Other metals, induding tita-
nium, molybdenum, or chromium, may be
added in small proportions. Cobalt alloys are
desirable for applications in the aircraft, auto-
mobile, and electrical industries because of
theirgreatstrength and resistance to oxidation.
The unusual hardness of the matrix that
increases with temperature makes this com-
posite suitable for use in production ofsaws,
cutters, drilling bits, grinding wheels, tunnel-
ing tools, and high-speed dental drills.
Manufacturing and use ofcemented carbide
materials, such as in the production and use of
cutting and grinding tools, results in
occupational exposure tohardmetaldust.
Workers exposed to cobalt or hard metal
dust are at risk ofdeveloping avariety ofres-
piratory diseases. These include reactive air-
ways disease (occupational asthma) and the
parenchymal diseases, such as giant cell
interstitial pneumonitis, bronchiolitis oblit-
erans, hypersensitivity pneumonitis, and
interstitial fibrosis. Some authors use the
term hard metal disease (HMD) to refer to
all the respiratory diseases secondary to
exposure to hard metal dust (63,64). Others
restrict the term to parenchymal manifesta-
tions in hard metal workers exclusive ofthe
obstructive disorders (65). There is substan-
tial overlap in pathologic consequences of
hard metal exposure, with many occurring
concurrently. The following discussion will
focus on the parenchymal disorders.
Parenchymal disease from hard metal dust
exposure was first recognized in Germany in
the 1940s (66). Subsequently, case reports
and retrospective series documented the dis-
ease in other European countries and the
United States (66-69). Cross-sectional sur-
veys ofworkers in hard metal plants have
reported prevalences ofparenchymal disease
from 0.7 to 13% (70-73). Comparison
across studies, however, is difficult due to
variations in exposure history, diagnostic cri-
teria, and referent populations. Cobalt-
associated pneumoconioses have recently
been recognized in dental technicians
(74-76). These exposures are typically mixed
exposures ofchromium cobalt alloys. In 1995
a Swedish cross-sectional study reported that
16% ofdental technicians who were exposed
to cobalt chromium molybdenum dust for at
least 5 years demonstrated radiologicevidence
ofpneumoconiosis.
Clinical symptoms of hard metal
parenchymal disease may occur subacutely
with the insidious onset ofcough, exertional
dyspnea, and weight loss. Symptoms may be
exacerbated by workplace exposures. Early in
the disease, removal from work may lead to
resolution ofsymptoms (77), with recurrence
upon return to work (78). Long-term expo-
sure results in increasing dyspnea, restrictive
lungvolumes, reduction in diffiusing capacity,
and eventual interstitial fibrosis. In a retro-
spective study, Posgay et al. (79) reviewed 30
years ofscreening ofexposed workers in the
hard metal industry. No correlation was
found between intensity or duration ofexpo-
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sure and the stage and progression of
pulmonaryfibrosis. In 45% ofthe cases, there
was progression ofthe fibrosis after cessation
ofthe exposure (79). Death from pneumonia
(80) and recurrence ofgiant cell interstitial
pneumonitis (81) have been reported in
HMD lung transplant recipients.
Pathologic findings have shown either
desquamative interstitial pneumonitis or
giant cell interstitial pneumonitis with or
without bronchiolitis obliterans, and varying
degrees of interstitial fibrosis (82-84).
Sarcoidlike noncaseating granulomas have
also been reported (85,86). BAL is useful in
the diagnosis oflung disorders from hard met-
als and/or cobalt. A typical feature in BAL
fluid and biopsy specimens is the presence of
bizarre, cannibalistic, giant, multinucleated
cells. These are considered a hallmark ofthe
disease and also classically seen in giant cell
interstitial pneumonia. Inflammatory cells are
increased and T-lymphocytes counts may be
normal or increased with inverted helper/sup-
pressor ratio (87-89). The persistence of
alveolitis and high numbers ofeosinophils at
BAL, despite cessation ofexposure, may sug-
gest a poorer prognosis (87). Although BAL
can be useful, some authors argue BAL is
insufficient for diagnosis (88).
The pathogenesis ofHMD is unclear. An
immunologic mechanism is suggested by the
small percentage ofworkers affected, inver-
sion ofhelper:suppressor T-cell ratios on
BAL, and known sensitizing capacity of
cobalt. Additionally, in vivo studies using
cobalt salts have shown positive lymphocyte
proliferation responses in individuals with
positive patch test reactions (90-92). Genetic
factors may also play a role in HMD
Potolicchio et al. (93) reported recently an
association between susceptibility to HMD
and the allelic substantiation ofa glutamic
acid in position 69 of the HLA-DP beta
chain. This finding distinguished a subgroup
of cobalt-exposed individuals at risk for
HMD, independent from the more common
allergic reaction, and analogous to the risk
that this allelic substitution confers on
workers exposed to beryllium (34,35).
Alternatively, an interaction between
cobalt and tungsten carbide underlies recently
proposed physicochemical theories (94).
Most cases ofhard metal parenchymal disease
occur in workers exposed to cobalt mixed
with metallic carbides. Cobalt exposure alone
has rarely been associated with parenchymal
lung disease. This has led to the widespread
belief that simultaneous inhalation ofother
metals such as tungsten carbide are essential
for development ofparenchymal disease (95).
Experimental evidence has shown that the
toxicity ofcobalt is enhanced in the presence
of metallic carbides such as tungsten carbide
(94,96,97). In rats, intratracheal instillation
oftungsten carbide-cobalt powder acutely
induces a severe alveolitis and fatal pul-
monary edema similar to that seen with crys-
talline silica (97). The alveolitis persists for at
least 1 month, and repeated exposure results
in histopathologic evidence offibrosis (98).
In contrast, instillation ofcobalt or tungsten
alone produces only moderate acute inflam-
mation and minimal delayed reaction.
In vitro, cobalt (99) and metallic carbides
(100) interact with oxygen to produce toxic
activated oxygen species. Since cobalt is inef-
ficient in transfer of electrons to oxygen,
Lison et al. (100) have suggested that tung-
sten carbide may act as an electron carrier to
transfer electrons from cobalt to oxygen.
Consequently, production ofreactive oxygen
species and free radicals may be responsible
for pulmonary damage. The observation that
few exposed workers develop interstitial dis-
ease may be explained by variability in indi-
vidual antioxidant defenses, although this
theory requires further testing. The necessity
ofan interaction between cobalt and other
components in the pathogenesis of HMD,
however, has recently been challenged by
reports ofinterstitial lung disease in diamond
polishers highly exposed to fine cobalt pow-
der without tungsten carbide (101-104).
Additionally, in vitro, cobalt ions are capable
of causing oxidative changes (105) in the
absence oftungsten carbide.
Industrial hygiene surveys suggest cobalt
levels are frequently underestimated and are
higher than the threshold limit value (TLV)
(106,107). Poorly regulated dust concentra-
tions in a hard metals factory have been asso-
ciated with pulmonary abnormalities and
severe illness (108). Neutron activation
analysis ofBAL fluid, blood, urine, toenails,
pubic hair, and sperm has been used, with
variable success, in monitoring exposure
(109) and diagnosis of HMD (110). The
clinical utility of these measures remains to
be proven. In view oftheir possible interac-
tion, more stringent exposure level limits for
the combination ofcobalt and tungsten car-
bide than for the individual components are
warranted (111).
Copper
Despite the abundance and widespread use
ofcopper, respiratory illness is infrequently
associated with its use. Inhalation ofcopper
dusts and fumes may result in upper respira-
tory tract irritation and ulceration or perfora-
tion ofthe nasal septum (112). Metal fume
fever (see section below), with symptoms of
chills, muscle aches, nausea, fever, cough,
and weakness, also may result from exposure
to copper fumes (113). A recent longitudinal
study ofworkers in a copper refinery, how-
ever, showed no increase in respiratory
diseases (114).
Interstitial lung disease has been described
in Portuguese vineyard workers who spray an
antimildew agent, referred to as Bordeaux
mixture, containing a copper sulfate solution
(115). Some workers with vineyard sprayers'
lung may be asymptomatic, with only small
nodular basilar densities on chest radiographs.
Others experience insidious onset offatigue,
anorexia, weight loss, and dyspnea. Chest
radiographs show a diffuse miliary or nodular
pattern. Acute cases present with fever,
cough, purulent sputum, and hemoptysis.
Nodular infiltrates, consolidation, and even-
tually cavitation are seen on chest radiographs
(115-117). Chronic forms result in con-
glomerate masses and massive pulmonary
fibrosis. Pathology shows granulomatous and
fibrotic lung lesions (115,117). Hepatic
involvement, including fibrosis, angiosar-
coma, and micronodular cirrhosis (118), and
an increased incidence oflung cancer (116)
have also been described.
The mechanisms responsible for copper
toxicity have not been well defined.
Endotracheal exposures in rats to metallic
copper oxide or dust resulted in diffuse nodu-
lar and interstitial fibrosis (119). In mice,
intratracheal instillation ofcopper smelter
dust resulted in a severe but transient inflam-
matory reaction and inhibition ofTNF-a
(120). In rats, intratracheal instillation of
copper indium diselenide, a compound used
in the semiconductor industry, causes moder-
ate inflammatory lesions and hyperplasia of
the alveolar type 2 cells (121). Direct toxicity
may result from generation ofreactive oxygen
species, leading to free radical damage of
nucleic acids and oxidative modification of
lipids and proteins (122).
In comparison to some ofthe other metals,
such as cobalt or beryllium, copper exposure
appears more benign, with infrequent descrip-
tions ofpulmonaryparenchymal disorders.
Iron
Occupations exposed to iron include mining,
smelting, and steel making. Pulmonary dis-
ease from the inhalation of iron oxide dust,
referred to as siderosis, occurs in the manu-
facture of iron oxide, the preparation of
emery rock for grinders, and the use ofemery
wheels and the polishing ofjewelry with
rouge. Welders may also develop siderosis
from iron oxide fumes, especially ifworking
in confined spaces. Siderosis is generally
assumed to be a benign condition and clinical
symptoms are usually minimal or nonexis-
tent. However, symptomatic and functional
changes, including restriction and decreased
compliance, may be present in some individ-
uals (123-125). Chest radiographs demon-
strate dense linear opacities resulting from
deposition ofradiodense iron oxide dust (1).
Radiographic abnormalities maydevelop in as
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little as 3 years ofhigh-intensity exposure but
usually develop over many years ofexposure
to iron oxide dust or iron fumes (126).
Following removal from exposure, radi-
ographic abnormalities may improve (127).
Reports offibrosis on pathology have been
described (128,129). Funahashi et al.
observed moderate to pronounced fibrosis in
5 of 10 symptomatic welders. In these indi-
viduals, energy-dispersive X-ray analysis
showed a large amount of iron in the lungs
and no silica, eliminating coexisting silicosis
as the etiology ofthe fibrosis (129). Although
no specific treatment exists, removal of iron
particles by BAL has been attempted in a
welder with siderosis to prevent further fibro-
sis (130). The effectiveness ofthis technique
remains to be proven.
Assessment ofhealth effects ofexposure to
iron oxide dust or fumes is complicated by
concurrent exposure to a number of other
toxic agents in most circumstances. Increased
respiratory symptoms and pulmonary func-
tion test abnormalities have been reported in
welders (131,132). The specific contribution
of iron and iron oxides to the findings
remains unclear.
The emerging literature suggests that
siderosis may not be as benign a pneumoco-
niosis as reported in texts. Unfortunately,
because siderosis is often considered a benign
pneumoconiosis, the pathogenesis of iron-
induced pulmonary disease has not been
studied in detail. However, experimental evi-
dence provides some insight. In rats, inhala-
tion ofhigh concentrations oflow toxicity
dusts, including carbonyl iron, was associated
with sustained pulmonary inflammation,
impairment ofparticle clearance, and deficits
in particle clearance (133). Reactive oxygen
species may play a role in iron-induced pul-
monary toxicity, as iron is suspected to be an
important mediator in catalyzing asbestos-
induced production ofreactive oxygen species
in the lung (134). In addition, in vitro, iron
sequestration by AMs may protect nearby
cells from exposure to potentially cytotoxic
iron-catalyzed oxidants (135). Recently, Lay
and colleagues (136) performed experimental
bronchoscopic instillation offerric oxide par-
ticles in humans. BAL postinstillation was
characterized by subclinical elevations in neu-
trophils, AMs, lactate dehydrogenase, and
protein, which resolved within 4 days. The
instilled particles contained small amounts of
soluble iron and possessed the capacity to
catalyze oxidant generation in vitro.
In summary, although traditionally con-
sidered abenign pneumoconiosis, siderosis may
result in symptomatic and functional deficits in
some individuals. As suggested in cadmium
and cobalt exposures, oxidant-induced cytotox-
icity may play a role in pathogenesis of
pulmonary disorders associatedwith iron.
Mercury
Known as quicksilver to the ancients,
mercury was named after the fleet-footed
messenger to the gods. Its symbol, Hg, is
derived from the Latin word hydrargyros,
meaning liquid silver. It is a heavy (MW =
200.6), relatively unreactive transition metal
obtained from cinnabar ore. Its neurotoxic
effects were evident in early cinnabar miners,
whose workday was shortened to 6 hr to
decrease exposure.
Mercury has many uses today in the
electrical industry for the manufacture of
mercury vapor lamps, transformers, rectifiers
and dry cell batteries; in the production of
scientific equipment; and as a catalyst in
polyurethane production. It is important in
the production ofexplosives, in metallurgic
laboratories, in high-frequency induction fur-
naces, in the electrolysis process, in pharma-
ceuticals and dental amalgam production, in
photoengraving, paints, and metal smelting,
in fungicides and algaecides, and as a paper
pulp preservative (1).
Exposures occur from accidental spills at
work or from work in confined spaces. Do-it-
yourselfat-home extraction ofgold or silver
from mercury amalgams contributes to on-
going case reports ofaccidental poisonings.
Although mercury can be absorbed from dental
amalgams, large epidemiologic studies ofadults
in Sweden found no significant impairment of
renal or immune function related to amalgams
(137-139). However, significant urinary Hg
dose effects were found for poor mental con-
centration, emotional lability, somatosensory
irritation, and mood scores among dentists
workingwith amalgam (140,141).
Mercury exists in three forms in nature:
elemental mercury, which is a silver liquid
and easily vaporized; organic mercury com-
pounds such as MeHgCl and EtHgCl; and
inorganic mercury salts such as HgC12.
Inhalation is the most significant route of
absorption for elemental mercury, whereas
gastrointestinal absorption is important for
the inorganic salts, and organic mercury is
present in food. The toxicity of mercury is
related to its ability to covalently bind and
reduce sulfur and sulfhydryl groups on pro-
teins and enzymes, thus inactivating them
and leaving the cell unprotected against oxi-
dant injury (142). Mercury also binds to car-
boxyl, amide, amine, and phosphoryl groups
on proteins to form protein-inorganic mer-
cury complexes. The acute short-term effects
ofhigh-dose elemental mercury vapor expo-
sure are pulmonary. Exposure causes severe
airway irritation, leading to tracheobronchitis,
bronchiolitis, and in some instances, pul-
monary edema and death. Although under
most circumstances exposure to mercury
vapor does not cause permanent lung dam-
age, chronic interstitial fibrosis may develop
in severe cases (1). Acute poisoning with
inorganic mercury usually results from inges-
tion, with gastrointestinal ulceration and
necrosis, and renal failurewithin 24 hr (143).
Despite our knowledge ofthe toxicity of
mercury vapor, cases ofacute mercury poison-
ing continue to be reported. A recent report
(144) from Korea describes a patient who
developed adult respiratory distress syndrome,
and subsequent pulmonary fibrosis and neuro-
logic changes, following exposure to mercury
vapor treatment for hemorrhoids. An Indian
infant 5 months ofage presented with acute
chemical pneumonitis with bilateral pneu-
mothoraces following mercury vapor exposure
at home (145). A report from Turkey
described the development oftoxic epidermal
necrolysis and erythema multiforme with ele-
vated plasma and urine mercury levels in a
family exposed to mercury vapor at home
(146). However, several surveys ofoccupa-
tionally exposed workers have presented more
reassuring data of an absence oflong-term
effects in a monitored setting. One studycom-
pared renal and immune markers in 41 mer-
cury-exposed chloralkali workers with 41
unexposed controls. Although workers had
higher mercury levels in plasma erythrocytes
and urine, levels of urine albumin and IgG
were similar in both groups. Six subjects had
low titer antinuclear antibodies; however, only
one was in the exposed worker group. No
other autoantibodies, antiglomerular basement
membrane (anti-GBM) antibodies, or circulat-
ing immune complexes were found in either
group (147). Another study compared 34
mercury-exposed workers from a fluorescent
light bulb factory to 35 unexposed workers.
Urinary mercury excretion was higher in
exposed workers, but urine mercury levels had
dropped from 36 pg Hg/L in 1978 to 6 pg
Hg/L in 1994. Exposed workers did show
lower levels ofthe activation marker CD25 on
peripheral blood mononuclear cells and
decreased blood TNF-a levels, which corre-
lated weakly to current urine mercury levels
(148). Another study evaluated 33 workers
with urine mercury <50 pg/gcreatininefrom a
mercury-producing plant in Brazil. Although
workers showed a decrease in peripheral circu-
lating CD4+ cells, T-cell proliferation to
phytohemagglutin was normal (149).
Both animal and in vitro studies have
demonstrated that programmed cell death
(apoptosis) is induced by mercury and may
be responsible for many of the associated
immunosuppressive and neurotoxic effects.
An extensive literature is emerging on the
apoptotic mechanism in mercury-related dis-
ease, potentially linking it to autoimmune,
pulmonary, neurologic, and renal effects.
Both human lymphocytes and monocytes
incubated with MeHgCl for 24 hr exhibit
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flow cytometric evidence of apoptosis.
Although cells continued to generate reactive
oxidative species (ROS), the number ofcell
thiols and free sulfhydryl groups able to
reduce these ROS were diminished
(150,151). In monocytes, phagocytic activity
dropped as well (151). The authors conclude
that a key event in cell apoptosis induced by
mercuric compounds is the depletion ofthiol
reserves, which predisposes cells to ROS dam-
age and activates death-signaling pathways.
Studies with EtHgCI and PhHgCI and
T cells produced similar dose-dependent
results. Recent studies in the brain have
demonstrated accelerated spontaneous apop-
tosis ofimmature astrocytes by HgC12 added
to rat brain cell cultures (152). DNA synthe-
sis was decreased, and associated with calcium
influx and tyrosine phosphorylation by 10
pM HgCl2 (153). Apoptotic cerebellar gran-
ule cells were described in rats rendered ataxic
by MeHgCl (154). Thus, it is likely that the
acute and chronic effects ofmercury poison-
ing are due in part to mercury-induced apop-
tosis ofcritical resident cell populations. Such
findings suggest that transcriptional regula-
tion may be affected by mercury and, in turn,
link it to changes in cytokine and inflamma-
torymediatorproduction (155-160).
In the lung, functional experiments
performed with murine macrophages demon-
strate a dose- dependent increase in IL-1
secretion after 6- to 24-hr incubation with
HgC12 up to 10-5 M (156). Inducible nitric
oxide synthase and nitric oxide production by
murine macrophages is suppressed at 0.1, 1,
and 10 jiM concentrations ofmercury (157).
Both organic methylmercury and inorganic
mercuric chloride are lethal to murine
macrophages at a concentration of20 pM and
reduce interferon-a and interferon-3 protein
synthesis in a dose-dependent manner.
Random migration and phagocytosis are sup-
pressed with lower concentrations ofmethyl
mercury (158). Electron microscopy of
methyl mercury-exposed cells demonstrate
uptake ofmercury, with deposits in lysosomes
and dispersion in the cytoplasm and nuclei.
Low concentrations ofHg2+ also cause dose-
dependent histamine release within 60 min of
incubation in human blood basophils, isolated
tissue mast cells, basophil (KU-812), and mast
cell lines (HMC-1) (159,160).
In summary, pulmonary mercury toxicity
occurs primarily from the accidental inhalation
ofelemental mercury vapor, causing acute air-
way irritation and rare episodes ofpulmonary
edema, chronic interstitial fibrosis, or death.
The pathogenesis ofthese effects involves in
part the depletion ofthiol reserves, with con-
comitant oxidant injury and secondary apop-
tosis ofcritical resident cell populations. In the
lung, animal studies also demonstrate impaired
macrophage cell function and death.
Metal Fume Fever
Metal fume fever is an inhalation fever
syndrome long recognized in metal workers. It
was first described in the mid-1800s as brass
founders' ague in brass foundry workers, and
in the 1900s in welders ofgalvanized steel,
particularly in the shipyard industry (161).
Although exposure to respirable fumes ofzinc
oxide is the most common and best-character-
ized cause ofmetal fume fever, other metal
oxides including arsenic, boron, cadmium,
chromium, copper, magnesium, manganese,
nickel, and titanium have been suggested to
cause the disease (1). Ofthese, magnesium
oxide is probably the most strongly associated;
however, these exposures are rare.
The condition is very common among
welders, with onset of symptoms typically
4-12 hr after the inhalation ofhigh levels of
respirable zinc oxide particles. Symptoms
begin with a sweet or metallic taste in the
mouth, throat irritation, cough, dyspnea,
malaise, fatigue, myalgias, and arthralgias.
Later, fever from 102 to 104°F develops, asso-
ciated with profuse sweating and shaking
chills. The syndrome may last 24-48 hr, with
asubsequent short-lived tolerance to zincoxide
fumes that is lost after 1-2 days ofavoidance
(162). The syndrome is related to exposure
dose and not to sensitization to the metal, as
there is no latent period to develop symptoms.
High serum zinc levels were demonstrated in
two welders with metal fume fever, although a
dose-response relationship has not been fur-
ther characterized (163). One prior case report
(164) described early- and late-phase urticaria
and angioedema in a welder 34 years of age
who also developed metal fume fever.
Although this is suggestive of an IgE-mediated
response to zinc oxide, other direct mediators
such as complement split products could also
reproduce this finding.
Metal fume fever is now thought to be
cytokine mediated. The characteristic symp-
toms are elicited by a limited array of
cytokines produced in the lung as a direct
response to the inhaled zinc oxide fumes.
Recent studies have elegantly identified the
cytokines involved, reproduced the character-
istic symptoms in vivo, and replicated the
cytokine response in vitro. Blanc et al. (165)
performed 26 welding exposures in 23 sub-
jects and compared postexposure cytokine
levels in BAL fluid at 3, 8, or 22 hr after
exposure. They found that TNF levels were
highest at 3 hr after exposure, but exhibited a
significant exposure-response relationship to
zinc exposure at each time period. IL-8 was
significantly elevated at 8 hr postexposure and
correlated with increased BAL fluid polymor-
phonuclear leukocytes (PMNs). IL-6 was sig-
nificantly elevated at 22 hr postexposure.
Although IL-1 was detected in BAL fluid, it
did not demonstrate an exposure-response
relationship to the zinc fumes. The same
researchers compared lavage findings from
subjects exposed to purified zinc oxide fuimes
or to air, at 3 hr (166) and 20 hr (167) after
exposure, with similar results (165). In one
study, cigarette smoking was not associated
with exposure-sham differences in BAL
TNF-a or IL-8, but there was a packs-per-
day-dependent increase in BAL supernatant
IL-1 postexposure compared to sham.
An interesting study recently examined
the clinical effects and cytokine response of
exposure to low concentrations ofzinc oxide
within the TLV of 5 mg/m3 for zinc oxide
fume (168). Thirteen resting naive subjects,
on separate days, inhaled air, 2.5 and 5
mg/m3 furnace-generated zinc oxide fume for
2 hr. Oral temperature rose following both
zinc oxide exposures, as did plasma IL-6 levels
following the 5 mg/m3 dose. Plasma levels of
TNF-a, however, were unaffected. Symptom
scores for myalgias, cough, and fatigue
peaked 9 hr after the 5 mg/m3 dose. The
authors concluded that a 2-hr inhalational
exposure to zinc oxide at the TLV of
5 mg/m3 still produces fever, symptoms, and
a rise in plasma IL-6 consistent with metal
fume fever.
Workers exposed to fumes containing
zinc oxide also exhibit small decrements in
pulmonary function. A comparison of 57
exposed and 55 nonexposed workers in a
Belgian steel plant showed no significant dif-
ference during the day shift. However,
exposed workers in the night shift exhibited a
small drop in vital capacity, in FEVI, and in
respiratory resistance with oscillation fre-
quency compared to the unexposed workers
(169). Although the changes oflungvolumes
and expiratory flows were related to differ-
ences in initial values between exposed and
unexposed workers, the decrease in FEV,
seen in the exposed workers was maintained
the day following exposure. The authors con-
clude that these small effects on pulmonary
function represent a subclinical response to
inhaled zinc oxide. Older studies of acute
high-dose exposure have demonstrated a 50%
reduction in vital capacity and a large fall in
FEV, occurring 4-6 hr after specific inhala-
tion challenges ofzinc oxide fumes (170).
The cumulative data suggest that effects
of zinc oxide on pulmonary cytokines are
mediated by mononuclear cells, presumably
the resident AMs. Human mononuclear cells
U937 exposed to zinc oxide in vitro release
TNF in a dose-dependent manner at 3, 8,
and 24 hr postexposure. IL-8 is increased at 8
and 24 hr. This pattern ofcytokine release is
consistent with in vivo observations in metal
fume fever (171).
Exposure to zinc oxide fumes also causes
an infiltration ofneutrophils into the airway.
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In vitro exposure ofhuman PMNs to Zn2+
and to ZnO for 2 hr stimulates the formation
ofoxygen radicals, as monitored by luminol-
amplified chemiluminescence via a PLA2
pathway (172). Zn2+ has been shown previ-
ously to bind to and stimulate the activity of
group I but not group II phospholipase A2
(173). The selective stimulation of group I
PLA2 by Zn2+ corresponds to binding of
these phospholipases to a zinc-affinity col-
umn, whereas group II PLA2 remains
unbound. This may be the critical step in
stimulating oxygen radical generation by
PMNs exposed to zinc oxide, which in turn
may contribute to the pathogenesis of zinc
fume fever.
In summary, metal fume fever is most
commonly caused in welders by exposure to
respirable fumes ofzinc oxide. The disease is
mediated by elevated levels ofTNF, IL-8,
and IL-6 in the lung and is associated with an
influx ofPMNs and a transient fall in airflow.
Nickel
Nickel was discovered in 1751 by Alex
Cronstedt and derives its name from the
German word Kupfernickel (false copper). In
1913, Brearly in England invented the
process ofadding nickel and chromium to
iron to make stainless steel. Other industrial
uses for nickel include the manufacture of
glass, enamels, ceramics, nickel-cadmium bat-
teries, other nickel-based alloys, nickel elec-
troplating, manufacture of automotive,
aircraft, and machine parts, magnets, cata-
lysts, and welding (1). Nickel is a transition
metal, and hence exhibits several common
oxidative states that play an important role in
catalyzing biologic oxidative reactions. Nickel
exists as relatively insoluble Ni3S2 and NiO
and soluble salts such as NiCl2, NiSo4.6H20,
NiO2, and NiSO4. Whereas water-soluble
nickel salts are rapidly excreted (t1/2 1 day),
the solid intermediates have a biologic half-
life of3 years. The biologic effects ofinsolu-
ble nickel salts are much greater than for
amorphous nickel solids. Nickel carbonyl,
Ni(CO)4, is an extremely reactive intermedi-
ate created in the Mond process, and it
decomposes to produce fine nickel powder.
Because of its reactivity, it produces acute
effects different from those of other nickel
compounds (174). The National Institute for
Occupational Safety and Health estimates
250,000 workers in the United States may be
occupationally exposed to nickel.
Inhalation is the primary route ofoccupa-
tional exposure to nickel compounds, which
accumulate preferentially in the lungs and the
kidneys. Nickel binding to the GBM blocks
anionic sites and leads to loss ofselectivity in
the filtration ofalbumin (174). In the upper
airway, nickel exposure is associated with
hyperplastic or polypoid rhinitis and sinusitis,
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anosmia, nasal septal perforation, and nasal
carcinoma. In the lower airway, epithelial
dysplasia, asthma, and lung cancer are the
most important disease correlates of nickel
exposure. High-dose exposure to nickel car-
bonyl causes chemical pneumonitis and pul-
monary edema. Death is unusual and
recovery is usually complete, although pul-
monary fibrosis may be a late sequela (1).
Nickel is a potent sensitizer, and roughly
10% ofthe U.S. population is dermally sensi-
tized to nickel, with higher rates reported in
women (174). Inhaled nickel-containing dust
can cause IgE-mediated occupational asthma
and rhinosinusitis (175), which are exten-
sively reviewed elsewhere in this monograph.
Of greater interest is why occupational
asthma related to nickel is so rarely reported,
given its high potential for cutaneous sensiti-
zation. One explanation may relate to the
lack of awareness of nickel asthma among
clinicians. There may be mechanistic explana-
tions as well. For example, it is likely that part
of that difference resides in the different
routes ofexposure (dermal vs inhalational)
and the functional capabilities ofthe resident
antigen-presenting cells. Human epidermal
Langerhans cells are many times more potent
than peripheral blood monocytes at inducing
T-cell responses to nickel sulfate (176). AMs
are normally poor antigen presenters and less
efficient than peripheral blood monocytes,
which may also explain the low incidence of
nickel-specific IgE-mediated asthma in
exposed workers.
Nickel refinery workers are exposed to
both insoluble and water-soluble nickel
species at work, including NiSO4.6H20 and
nickel and copper oxides (177). These work-
ers also have a significantly higher lung bur-
den ofnickel as measured in biopsy specimens
by electrothermal atomic absorption spec-
troscopy. Biopsies ofthe right lower lobe in
15 former nickel refinery workers showed an
arithmetic mean of 82 ± 252 pg nickel/g wet
weight compared to 0.74 ± 0.44 ,ug/g in 10
unexposed normal subjects (178). One study
compared the lung nickel burden of 11 nickel
refinery workers (ofwhom 10 had died of
lung cancer), 2 stainless steel welders, and 30
normal subjects. The median nickel concen-
trations for normals were 0.020-0.040 pg/g
wet weight. Median nickel concentrations in
the former refinery workers were 112-5,860
times higher, and 500-fold higher in the stain-
less steel welders (179). Another study of
urban dwellers (n = 17) demonstrated an aver-
age of0.22-1.93 pg nickel/g dry weight of
lung tissue, with the highest concentration in
the upper lobes. Cigarette smoking and a his-
tory ofoccupational exposure significantly
increased levels (180).
Animal studies have helped elucidate
chronic effects of nickel inhalation. Mice
exposed to aerosols ofNi3SO2, NiO, or
NiSO4.6H20 demonstrated increased num-
bers oflung-associated lymph nodes and
increased antibody-forming cells at the higher
doses of NiO and Ni3S2. NiO and Ni3SO4
both decreasedAM phagocytic activity (181).
Rabbits exposed to metallic and soluble
nickel (NiCI2) increased both the number
and size oftype II alveolar cells, increased the
production ofsurfactant, and functionally
activated the AM (182). After 3 and 6
months of exposure to metallic nickel, the
AM were overfed and inactive. These effects
were also seen with cobalt and chromium. An
in vitro study of nickel hydroxy carbonate
(NiHC) showed increased TNF-a and IL-6
secretion at noncytotoxic nickel concentra-
tions (183).
Studies of nickel-specific human T-cell
lines and clones have helped elucidate the
immunologic effects of this metal. Most
nickel-specific T-cell clones are CD4+
CD45RO+ (memory) T cells, and only
nickel-sensitized individuals also demonstrate
nickel-specific CD8+ cells (184). Sensitized
subjects demonstrate individually skewed use
ofvariable beta chain (V3) elements of the
T-cell antigen receptor. In one recent study
V1l was expressed in most nickel-specific
CD8+ cells (185). In another small study, the
V1317 element was over-represented following
in vitro stimulation with NiSO4 or NiSO4-
human serum albumin hapten. Unique
sequences in the CDR1 ofthe T-cell antigen
receptor on nickel T-cell clones were similar
to those known to be nickel-binding motifs
in proteins or peptides, leading the authors to
suggest that Ni2+ ions bridge the V,17-
CDR1 loop to the MHC, thus creating a
superantigen-like enhancement of weak
T-cell receptor-peptide contacts (186).
Researchers from Finland evaluated TAPI
and TAP2 gene expression in 55 nickel-sensi-
tive and 54 nickel-nonsensitive subjects
(187). They found allelic and phenotype fre-
quencies ofTAP2B significantly increased
(p < 0.019 and p < 0.012) in nickel-sensitive
subjects, with a relative risk (RR) = 2.7. The
allelic frequency ofTAP2C was decreased
among nickel-sensitive subjects (p < 0.016),
with an RR for nickel sensitivity of 0.18.
These studies suggest that sensitivity to nickel
is genetically determined, similar to other
allergic sensitization.
NiCl2 induces the gene transcription of
intercellular adhesion molecule-i (ICAM-1),
vascular cell adhesion molecule-1 (VCAM-
1), and E-selectin in endothelial cells (188).
The same authors also demonstrated that
incubation of HUVEC cells with NiCI2 or
CoC12 activates nuclear factor kappa B (NF-
KB), a transcription factor involved in the
inducible expression of adhesion molecules
and cytokines. Furthermore, NiCI2 induced
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dose-dependent mRNA production and
protein secretion ofthe NF-xB-controlled
proinflammatory cytokine IL-6. The process
was inhibited by the antioxidant pyrrolidine
dithiocarbamate, indicating the involvement
ofredox-dependent mechanisms (189). The
authors conclude that nickel and cobalt trig-
ger a distinct program ofgene transcription,
mediated in part by the generation ofreactive
oxygen intermediates and subsequent induc-
tion of NF-icB, that finally results in the
inflammatory activation ofthe endothelium.
Interestingly, serum and urine NiSO4
levels following nickel challenge are the same
in both sensitized and normal females (190),
suggesting that altered nickel metabolism does
notdetermine development ofdisease. Acom-
parison ofcytokine responses to a 5% NiSO4
patch test among five patientswith atopic der-
matitis and seven nonatopic patients, both
with nickel contact allergy, showed similar
increased expression ofy-interferon, IL-2, and
IL-4. The nonatopic patients were distin-
guished by increased expression of IL-10,
whereas the atopic patients showed no
increase (191). These findings were replicated
by Cavani et al. (184); nickel-specific T-cell
clones prepared from nonallergic subjects dis-
played lower interferon-y and higher IL-10
production compared with T-cell clones from
allergic patients. These findings indicate that
absence ofdisease is not due to the inability to
recognize orpresent nickel as an antigen, since
both allergic and nonallergic individuals are
capable ofgenerating nickel-specific T-cell
clones. The difference may reside in the
cytokine profile generated by these clones in
response to nickel exposure. Another study
demonstrated a strict requirement for IL-4 to
induce more IL-4 production in nickel-spe-
cific human CD4 cells (192). IL-4 induced
and sIL-4R or anti-IL4 antibody abolished
priming for IL-4 production, even in NiSO4-
specific CD4+ cells from sensitized individu-
als. These results show that the IL-4 pathway
ofmemory T cells retains a remarkable plas-
ticity, even in sensitized individuals, and sug-
gest methods of intervention. One hypo-
sensitization protocol in 21 patients with
nickel-allergic contact dermatitis, involving
ultraviolet B (UVB) treatment with or with-
out subcutaneous NiSO4 administration,
found clinical improvement with UVB treat-
ment that persisted in the group that was also
hyposensitized (193).
In summary, nickel is a highly sensitizing
metal primarily associated with IgE-mediated
sinusitis, dermatitis, and asthma but also
causes chemical pneumonitis, pulmonary
edema, and rarely pulmonary fibrosis in high-
dose exposures. Response or tolerance to
nickel, as in othermetals, is in part determined
by individual genotype and cytokine response
tO the metal.
Future Directions
Based on these new developments related to
the individual metals above, several future
directions become apparent. First, there is an
increasing need for clinical investigators in
collaboration with bench investigators to use
knowledge ofthe immunologic and inflam-
matory basis ofmetal-induced parenchymal
disease to guide the development ofnew bio-
logic markers ofexposure, effect, disease, and
prognosis. Metals can, in many instances,
leave a telltale "fingerprint" on the exposed
individual's immune system that can be uti-
lized in exposure and disease detection, as in
the examples ofberyllium, cobalt, and nickel.
Second, there is a need to link our under-
standing of immune mechanisms with the
work being done on inflammatory mecha-
nisms toward a unified understanding ofdis-
ease pathogenesis due to metals. The metals
offer a unique opportunity to examine the
relationship between environmental expo-
sure/dose and human genetic susceptibility.
This leaves researchers several future tasks:
a) to better detail and characterize human
exposure, b) to examine gene alleles that may
confer risk in individuals exposed to these
metals, and c) to unite the data generated on
exposure with understanding ofthe human
genome. Through a better understanding of
both pathogenesis and exposure-response
relationships, we may be better able to
prevent metal-induced disorders.
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